Highlights From EAN 2023

Ofatumumab presentations

Five-Year Safety of Ofatumumab in People Living With Relapsing Multiple Sclerosis

Ofatumumab, interferon ß1 and glatiramer acetate as first-line treatment in everyday practice: the AIOLOS study

Five-Year Efficacy Outcomes of Ofatumumab in Relapsing MS Patients: Insights From ALITHIOS Open-label Extension Study

Effect of Longer-term Ofatumumab Treatment on Disability Worsening and Brain Volume Change

Multiple Sclerosis